CHMP recommends a label update for Novo Nordisk's Ozempic after the STRIDE study shows walking improvements in T2D patients with PAD.

A small Italian study has found an Ozempic-style drug can halve the number of migraine days suffered in a month.

A clinical trial has shown that Ozempic improves blood glucose levels and weight loss in overweight type 1 diabetics who use ...

There’s no such thing as "natural Ozempic." While supplements like psyllium, berberine, and glucomannan are paraded as ...

A NEW weight loss jab that only needs to be taken once monthly leads to “substantial weight loss”, according to early trials.

Novo Nordisk NVO announced that it has submitted a regulatory application to the European Medicines Agency (EMA) seeking ...

Novo Nordisk dropped a pile of scientific data on three new experimental weight-loss drugs, including an oral one, showing what appears to be a strategic "something for everyone" plan of attack from ...

CHMP recommends approval of Novo Nordisk’s Ozempic for peripheral arterial disease: Bagsværd, Denmark Wednesday, June 25, 2025, 15:00 Hrs [IST] Novo Nordisk, a leading global h ...

Amycretin, a new weight-loss treatment from Novo Nordisk, combines two hunger hormones, helping participants lose nearly ...

"Nearly 62% of adults with type 1 diabetes are either overweight or obese, which is associated with insulin resistance, suboptimal glycemic outcomes, and increased risk for cardio ...

Novo Nordisk on Friday said full results from early-stage trials show that its experimental drug, amycretin, helped overweight and obese adults lose up to 24% of their weight as the Danish company ...

Novo Nordisk's U.S.-listed shares fell close to 6% Monday after the drugmaker revealed the latest results for a new ...